What Serina Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 7 |
| Sells | 0 | 25 |
| Total trades | 0 | 63 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 8,868,795 |
| Disposed | 0 | 85,979 |
| Net activity | +0 | +8,782,816 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Brannan Stephen K. | Director | Jul 07 | Open-market buy · P | +1,000 | $2.03 | +$2.03K | 1,000 |
| Bailey Gregory | Director | Jun 17 | Derivative Conversion · C | +6,666,667 | $2.25 | +$15M | 8,564,382 |
| Bailey Gregory | Director | Jun 17 | Derivative Conversion · C | +1,770,805 | $2.25 | +$3.98M | 1,897,445 |
| Venkatesan Jay | Director | Jun 17 | Derivative Conversion · C | +224,152 | $2.25 | +$504K | 231,705 |
| Wilson Karen J | Director | Jun 12 | Open-market buy · P | +5,000 | $1.77 | +$8.85K | 10,100 |
| Wilson Karen J | Director | Jun 11 | Open-market buy · P | +5,100 | $1.75 | +$8.9K | 5,100 |
| Ledger Steven A | Chief Executive Officer | May 26 | Grant / award · A | +10,100 | $1.93 | +$19.5K | 10,100 |
| Wilson Karen J | Director | May 22 | Open-market buy · P | +10,000 | $1.93 | +$19.3K | 20,000 |
| Venkatesan Jay | Director | May 22 | Open-market buy · P | +589 | $1.78 | +$1.05K | 589 |
| Wilson Karen J | Director | May 21 | Open-market buy · P | +10,000 | $1.77 | +$17.7K | 10,000 |
| Marshall Richard Peter | Director | May 19 | Open-market buy · P | +12,183 | $1.65 | +$20.1K | 12,183 |
| Venkatesan Jay | Director | Mar 31 | Grant / award · A | +7,553 | $1.94 | +$14.7K | 7,553 |
| Bailey Gregory | Director | Mar 31 | Grant / award · A | +59,667 | $1.94 | +$116K | 126,910 |
| Moreadith Randall | Chief Scientific Officer | Mar 23 | Open-market sale · S | −6,500 | $2.86 | −$18.6K | 0 |
| Moreadith Randall | Chief Scientific Officer | Mar 23 | Exercise / conversion · M | +6,500 | $0.06 | +$390 | 6,500 |
| Moreadith Randall | Chief Scientific Officer | Mar 19 | Open-market sale · S | −39,000 | $2.50 | −$97.5K | 0 |
| Moreadith Randall | Chief Scientific Officer | Mar 19 | Exercise / conversion · M | +39,000 | $0.06 | +$2.34K | 39,000 |
| Moreadith Randall | Chief Scientific Officer | Feb 02 | Open-market sale · S | −6,500 | $3.03 | −$19.7K | 0 |
| Moreadith Randall | Chief Scientific Officer | Feb 02 | Exercise / conversion · M | +6,500 | $0.06 | +$390 | 6,500 |
| Moreadith Randall | Chief Scientific Officer | Jan 28 | Open-market sale · S | −6,500 | $3.57 | −$23.2K | 0 |
Loading...
